Emmanuel Bria, a Barbadian entrepreneur and representative of Summus Barbados, recently shared his transformative journey into the medicinal cannabis industry during the Cannabliss SVG 2025 conference in St. Vincent and the Grenadines. Standing amidst rows of meticulously cultivated cannabis plants at CannaSVG, the region’s largest licensed farm, Bria reflected on his evolving perspective. Initially skeptical about medicinal cannabis, he now champions its potential, provided it is grown and processed under stringent quality controls.
Bria emphasized that cannabis, inherently a medicinal plant, can become harmful if cultivated in toxic environments. ‘The plant absorbs everything in its surroundings,’ he explained. ‘If it’s exposed to contaminants like bacteria, fungi, or toxic elements, it’s no longer medicinal—it’s a time bomb.’ This realization reshaped his understanding of the industry, highlighting the critical need for rigorous testing and sterile cultivation practices to ensure safety and efficacy.
During the conference, Bria engaged with cultivators, manufacturers, and retailers, gaining firsthand insights into the discipline required to build a legitimate medicinal cannabis sector. He stressed that the industry’s primary focus should be on healing and addressing the needs of individuals suffering from chronic pain, post-surgery discomfort, and anxiety. ‘It’s about introducing a clean, safe, and fully organic product into the market,’ he said. ‘Consistent testing and quality assurance are non-negotiable.’
Bria’s journey was as much personal as professional. He admitted to unlearning preconceived notions and relearning the science behind medicinal cannabis. Now, his mission is to educate others in Barbados about its potential and the opportunities it presents. ‘We’re moving forward,’ he said optimistically. ‘It’s about healing people, and we’re going to fix the challenges along the way.’
His story underscores the growing importance of quality control and education in the burgeoning medicinal cannabis industry, as it strives to balance therapeutic benefits with public trust and safety.